James R. Kasinger Sells 1,089 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CRISPR Therapeutics Stock Up 2.0 %

CRSP stock opened at $49.00 on Thursday. The firm has a market capitalization of $4.16 billion, a PE ratio of -18.01 and a beta of 1.68. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The stock has a 50-day simple moving average of $47.14 and a two-hundred day simple moving average of $53.59.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The company’s revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.98) EPS. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on CRSP. Rodman & Renshaw began coverage on CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective on the stock. Truist Financial dropped their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Barclays dropped their price objective on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Finally, Needham & Company LLC dropped their price objective on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average price target of $75.19.

Institutional Trading of CRISPR Therapeutics

Large investors have recently modified their holdings of the business. Riggs Asset Managment Co. Inc. boosted its position in shares of CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Global Trust Asset Management LLC boosted its position in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC lifted its position in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. NBC Securities Inc. lifted its position in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after buying an additional 438 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.